Related Experiment Video

Updated: Jun 16, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including

Hiroshi Hirai1, Tsuyoshi Arai, Megumu Okada

  • 1Department of Oncology, Banyu Tsukuba Research Institute, Merck Research Laboratories, 3 Okubo, Tsukuba, Ibaraki, Japan. yrdyc661@yahoo.co.jp

Cancer Biology & Therapy
|January 29, 2010
PubMed

Insights

MK-1775, a Wee1 inhibitor, enhances chemotherapy by overriding DNA damage checkpoints in p53-deficient cancer cells. This combination therapy shows potent anti-tumor effects, supporting its clinical investigation.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • MK-1775 is a selective Wee1 inhibitor.
  • Previous studies demonstrated its efficacy in p53-deficient tumors when combined with gemcitabine, carboplatin, and cisplatin.
  • MK-1775 is currently in Phase I clinical trials.

Purpose of the Study:

  • To investigate the effects of MK-1775 on 5-fluorouracil (5-FU) and other DNA-damaging agents.
  • To determine the specificity of MK-1775's enhancement of chemotherapy in p53-deficient versus p53-wild type cancer cells.
  • To evaluate the in vivo efficacy of MK-1775 in combination with 5-FU or capecitabine.

Main Methods:

  • Assessing the cytotoxicity of MK-1775 combined with various DNA-damaging agents in p53-deficient and p53-wild type human colon cancer cells.
  • Measuring CDC2 Y15 phosphorylation and Histone H3 phosphorylation to evaluate checkpoint abrogation and mitotic entry.
  • Conducting in vivo studies using mouse models to assess anti-tumor efficacy and tolerability.

Main Results:

  • MK-1775 enhanced the cytotoxic effects of 5-FU specifically in p53-deficient colon cancer cells.
  • MK-1775 abrogated 5-FU-induced DNA damage checkpoints by inhibiting CDC2 Y15 phosphorylation and causing premature mitosis.
  • In vivo, MK-1775 potentiated the anti-tumor efficacy of 5-FU and capecitabine at tolerable doses, correlating with molecular markers.
  • MK-1775 also enhanced the effects of other DNA-damaging agents like pemetrexed, doxorubicin, camptothecin, and mitomycin C.

Conclusions:

  • MK-1775 selectively sensitizes p53-deficient cancer cells to 5-FU and other DNA-damaging agents.
  • The combination of MK-1775 with DNA-damaging agents warrants further clinical investigation for cancer treatment.
  • MK-1775 demonstrates potential as a chemosensitizer across various DNA-damaging chemotherapeutic agents.

More Related Videos

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors06:07

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors

Published on: August 5, 2022

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibitors of Bacterial DNA Synthesis01:28

Inhibitors of Bacterial DNA Synthesis

Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...